Sarepta must also run a post-marketing study for Elevidys to better assess the risk of serious liver injury in patients dosed ...

Aside from announcing layoffs, Sensei has decided to terminate its R&D work. The biotech has $25 million on hand, and ...

Artios Pharma is working on a pipeline of oncology assets, led by alnodesertib, currently being tested for second-line ...

There appears to be growing frustration about FDA Commissioner Marty Makary’s management style within the highest levels of ...

Priority voucher awardees and regulators could feel pressure to “meet the moment” as FDA watchers question the intent and ...

Bayer has let go of about 13,500 employees, including around 5,000 managers, since implementing a new operating model in ...

Merck has made several big-ticket deals this year, led by its $10 billion buyout of Verona Pharma in July, giving the pharma ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Altimmune’s pemvidutide showed “class-leading signals” in non-invasive assessments and has “potentially best-in-class ...

BMS and J&J first linked together in 2018 to develop factor X1a inhibitors as anti-coagulants. The three Phase III Librexia ...

In January, AbbVie and Calico’s fosigotifator failed to show significant signs of efficacy in the HEALEY ALS platform trial ...

The back-heavy deal includes a $5 million upfront payment for two novel T cell engagers, though the companies have yet to ...